A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

Table 1 Demographic data of patients and baseline measures (n = 122)

Baseline patients’ characteristics (n = 122)
Age, years		65 [58–72]
Weight, kg		68 [60–77]
Height, cm (n = 121)		170 [163–174]
Body surface area, m² (n = 121)		1.75 [1.64–1.93]
Carcinoembryonic antigen, μg/L (n = 111)		68.6 [11.8–271.3]]
Vascular endothelial growth factor, ng/L (n = 119)		169.6 [61.9–334.5]
C_trough bevacizumab, mg/L		15.5 [11.7–22.8]
Time to progression, months		10.6 [7.4–16.1]
Follow-up period, months		23.9 [14.7–35.3]
Gender	male	77 (63%)
	female	45 (37%)
World Health Organization Performance Status (n = 116)	0	63 (52%)
	1	51 (42%)
	2	2 (2%)
Primary tumor site	Colon	85 (70%)
	Rectal	37 (30%)
Combined chemotherapy	FOLFIRI	81 (66%)
	FOLFOX	21 (17%)
	LV5FU2	8 (7%)
	Others	12 (10%)

Results are expressed as median [interquartile range] for continuous variables or number (%) for categorical variables.
Abbreviations: n number of patients, FOLFIRI oxaliplatin, 5-fluorouracil, and leucovorin, FOLFOX irinotecan, 5-fluorouracil, and leucovorin, LV5FU2 leucovorin and 5-fluorouracil

ISSN: 1471-2407